News & Articles

Detecting lung cancer early with advanced flow cytometry

Our Most Recent News, Events, Press Releases

Latest Information

Latest Updates

bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

Proactive steps reinforce bioAffinity Technologies’ laser focus on accelerating CyPath® Lung sales growth in strategic national markets Decreases labor and overhead costs, including 38% workforce reduction in non-CyPath® Lung personnel at Company’s subsidiary laboratory SAN ANTONIO, Texas (March 6, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced targeted strategic actions to improve financial performance and accelerate the commercial growth of CyPath® Lung, the Company’s noninvasive test for early-stage lung cancer. The Company expects these measures to deliver approximately $4 million in annual cost savings at its subsidiary Precision Pathology Laboratory Services (PPLS), while increasing resources to...
Read More
Full Catalog of Prior Articles, News, Events, and Press Releases

Prior Articles

News & Articles

Precision Pathology laboratory Services

Learn More about CyPath® Lung

The CyPath® Lung Flow Cytometry Test is sold by Precision Pathology Laboratory Services, a bioAffinity Technologies company,  as a Laboratory Developed Test (LDT).

CyPath® Lung is a non-invasive test that assists clinical decision-making in lung cancer patients whose low-dose computed tomography (LDCT) has demonstrated a suspicious finding.

The test reveals the lung micro-environment by automated analysis of sputum using flow cytometry to characterize cell populations indicative of cancer in the lung.

Physician Portal

Patient Portal

How to Order

CyPath® FAQ

Subscribe for News from bioAffinity Technologies